Aluminum Hydroxide
This graph shows the total number of publications written about "Aluminum Hydroxide" by people in the URMC Research Network by year, and whether "Aluminum Hydroxide" was a major or minor topic of these publication.
Below are the most recent publications written about "Aluminum Hydroxide" by people in Profiles.
-
Brady RC, Treanor JJ, Atmar RL, Keitel WA, Edelman R, Chen WH, Winokur P, Belshe R, Graham IL, Noah DL, Guo K, Hill H. Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine. 2009 Aug 13; 27(37):5091-5.
-
Lopus SE, Bachand PA, Heyvaert AC, Werner I, Teh SJ, Reuter JE. Potential toxicity concerns from chemical coagulation treatment of stormwater in the Tahoe basin, California, USA. Ecotoxicol Environ Saf. 2009 Oct; 72(7):1933-41.
-
Crompton PD, Mircetic M, Weiss G, Baughman A, Huang CY, Topham DJ, Treanor JJ, Sanz I, Lee FE, Durbin AP, Miura K, Narum DL, Ellis RD, Malkin E, Mullen GE, Miller LH, Martin LB, Pierce SK. The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals. J Immunol. 2009 Mar 1; 182(5):3318-26.
-
Keitel WA, Campbell JD, Treanor JJ, Walter EB, Patel SM, He F, Noah DL, Hill H. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I-II randomized clinical trial. J Infect Dis. 2008 Nov 1; 198(9):1309-16.
-
Mullen GE, Ellis RD, Miura K, Malkin E, Nolan C, Hay M, Fay MP, Saul A, Zhu D, Rausch K, Moretz S, Zhou H, Long CA, Miller LH, Treanor J. Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS One. 2008; 3(8):e2940.
-
Pichichero ME. Improving vaccine delivery using novel adjuvant systems. Hum Vaccin. 2008 Jul-Aug; 4(4):262-70.
-
Lambert JS, Keefer M, Mulligan MJ, Schwartz D, Mestecky J, Weinhold K, Smith C, Hsieh R, Moldoveanu Z, Fast P, Forrest B, Koff W. A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects. Vaccine. 2001 Apr 30; 19(23-24):3033-42.
-
Evans TG, McElrath MJ, Matthews T, Montefiori D, Weinhold K, Wolff M, Keefer MC, Kallas EG, Corey L, Gorse GJ, Belshe R, Graham BS, Spearman PW, Schwartz D, Mulligan MJ, Goepfert P, Fast P, Berman P, Powell M, Francis D. QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine. 2001 Feb 28; 19(15-16):2080-91.
-
Mocan MZ, Mocan H, Fell GS, Junor BJ, Boyce BF. Autonomous hyperparathyroidism not associated with increased aluminum absorption. Isr J Med Sci. 1992 Jan; 28(1):24-6.
-
Bradbury MW, Deane R. Brain endothelium and interstitium as sites for effects of lead. Ann N Y Acad Sci. 1988; 529:1-8.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
|
